Foghorn Therapeutics Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -72.4% over 5Y.
today you would have $251.26▼ -74.9%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 6 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Year-end price | $5.40 | $4.72 | $6.45 | $6.38 | $22.87 | $20.27 | |
| P/S | 12.7x | 10.3x | 11.6x | 8.0x | 13.9x | 718.2x | 1735.5x |
| P/B | 9.8x | — | — | — | 2381.3x | 9.8x | 5.1x |
| EPS | -$1.18 |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| OCGNOcugen, Inc. | $1.04 | — | — | — | — | $352.67M |
| PALIPalisade Bio Inc | $2.00 | 3.2x | 2.9x | — | -51.37% | $348.54M |
| ENTAEnanta Pharmaceuticals Inc | $11.95 | — | 3.4x | — | -70.12% | $348.05M |
| UPBUpstream Bio, Inc. | $6.69 |
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer; and diffuse large B-cell lymphoma, as well as various acute myeloid leukemia and myelodysplastic syndrome. The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Company description provided by Yahoo Finance.
| -$1.58 |
| -$2.34 |
| -$2.62 |
| -$2.73 |
| -$6.23 |
| Profit margin | -474.75% | -240.33% | -383.24% | -288.17% | -566.27% | -7681.58% | -16000.00% |
| ROE | -104.59% | — | — | — | -97216.07% | -104.59% | -47.06% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 1.2x |
| — |
| -46.05% |
| $366.42M |
| SABSSAB Biotherapeutics, Inc. | $3.79 | 15.8x | 1.5x | — | -11.27% | $344.84M |
| IPSCCentury Therapeutics, Inc. | $1.89 | — | 1.5x | — | -49.65% | $342.23M |